The Albers Laboratory uses the olfactory system of mice and humans to explore early pathologic events of neurodegeneration.
Research Labs at the Healey Center
We take a multidisciplinary, basic science to clinic translational approach to designing patient-oriented experimental and clinical trials for aging, dementia, and other neurodegenerative disorders.
Borrowing from successes in cancer drug development, the Healey Center and NEALS faculty are leading the first ALS Platform Trial.
Clotilde Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) and to develop therapeutic strategies.
The MassGeneral Institute for Neurodegenerative Disease (MIND) is a research center for Alzheimer’s, ALS (Lou Gehrig’s), Huntington’s, Parkinson’s and other neurodegenerative diseases.
The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) consists of a Clinical Coordinating Center (CCC) at Mass General, a Data Coordinating Center (DCC) at the University of Iowa, and 25 other clinical sites.
Our laboratory focuses on identifying common mechanisms that cause neurodegenerative disease in order to identify novel therapeutic targets.
The Wainger Lab at Massachusetts General Hospital focuses on how abnormalities of motor and sensory neuron physiology contribute to diseases such as ALS and chronic pain.
Transforming Medicine Through Innovation
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.